The monoterpene carvacrol, the major component of oregano and thyme oils, is known to exert potent antifungal activity against the pathogenic yeast Candida albicans. This monoterpene has been the subject of a considerable number of investigations that uncovered extensive pharmacological properties, including antifungal and antibacterial effects. However, its mechanism of action remains elusive. Here, we used integrative chemogenomic approaches, including genome-scale chemical-genetic and transcriptional profiling, to uncover the mechanism of action of carvacrol associated with its antifungal property. Our results clearly demonstrated that fungal cells require the unfolded protein response (UPR) signaling pathway to resist carvacrol. The mutants most sensitive to carvacrol in our genome-wide competitive fitness assay in the yeast Saccharomyces cerevisiae expressed mutations of the transcription factor Hac1 and the endonuclease Ire1, which is required for Hac1 activation by removing a nonconventional intron from the 3= region of HAC1 mRNA. Confocal fluorescence live-cell imaging revealed that carvacrol affects the morphology and the integrity of the endoplasmic reticulum (ER). Transcriptional profiling of pathogenic yeast C. albicans cells treated with carvacrol demonstrated a bona fide UPR transcriptional signature. Ire1 activity detected by the splicing of HAC1 mRNA in C. albicans was activated by carvacrol. Furthermore, carvacrol was found to potentiate antifungal activity of the echinocandin antifungal caspofungin and UPR inducers dithiothreitol and tunicamycin against C. albicans. This comprehensive chemogenomic investigation demonstrated that carvacrol exerts its antifungal activity by altering ER integrity, leading to ER stress and the activation of the UPR to restore protein-folding homeostasis.F ungal pathogens represent a serious risk to the growing population of immunocompromised individuals resulting from the increasing success of organ and bone marrow transplantation, immune-suppressive cancer chemotherapy, premature births, and the AIDS pandemic. Candida albicans is a diploid ascomycete yeast that is an important commensal and opportunistic pathogen in humans. Systemic infections resulting from C. albicans are on the rise and are associated with mortality rates of 50% or greater despite currently available antifungal therapy (1-3). Current therapeutic options are limited to treatment with three longstanding antifungal classes, the polyenes, azoles, and echinocandins (4). These compounds target the specific fungal biological process of ergosterol metabolism (azoles and polyenes) and cell wall -1,3-glucan synthesis (echinocandins). However, these drugs have serious side effects such as nephrotoxicity and/or create complications such as resistance due to their fungistatic rather than fungicidal characteristics (4-6). There is, thus, an urgent need for new strategies to identify novel protein targets and bioactive molecules for antifungal therapeutic intervention.Plants are an interesting reservoir of s...